Pardanani A - Search Results

1

Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.

Pardanani A. Pardanani A. Am J Hematol. 2015 Mar;90(3):250-62. doi: 10.1002/ajh.23931. Am J Hematol. 2015. PMID: 25688753 Free article. Review.

2

Immunohistochemical studies of c-kit, transforming growth factor-beta, and basic fibroblast growth factor in mast cell disease.

Baek JY, Tefferi A, Pardanani A, Li CY. Baek JY, et al. Among authors: pardanani a. Leuk Res. 2002 Jan;26(1):83-90. doi: 10.1016/s0145-2126(01)00102-3. Leuk Res. 2002. PMID: 11734306

3

Bone marrow angiogenesis in systemic mast cell disease.

Baek JY, Li CY, Pardanani A, Butterfield JH, Tefferi A. Baek JY, et al. Among authors: pardanani a. J Hematother Stem Cell Res. 2002 Feb;11(1):139-46. doi: 10.1089/152581602753448603. J Hematother Stem Cell Res. 2002. PMID: 11847010

4

Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia.

Tefferi A, Mesa RA, Gray LA, Steensma DP, Camoriano JK, Elliott MA, Pardanani A, Ansell SM, Call TG, Colon-Otero G, Schroeder G, Hanson CA, Dewald GW, Kaufmann SH. Tefferi A, et al. Among authors: pardanani a. Blood. 2002 May 15;99(10):3854-6. doi: 10.1182/blood-2001-12-0154. Blood. 2002. PMID: 11986248 Free article. Clinical Trial.

5

Treatment of hypereosinophilic syndrome with imatinib mesilate.

Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Gleich GJ, et al. Among authors: pardanani a. Lancet. 2002 May 4;359(9317):1577-8. doi: 10.1016/S0140-6736(02)08505-7. Lancet. 2002. PMID: 12047970

6

Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis.

Pardanani A, Witzig TE, Schroeder G, McElroy EA, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Kyle RA, Greipp PR, Gertz MA, Rajkumar SV. Pardanani A, et al. Blood. 2003 Feb 1;101(3):827-30. doi: 10.1182/blood-2002-06-1698. Epub 2002 Sep 5. Blood. 2003. PMID: 12393530 Free article.

7

Systemic mast cell disease without associated hematologic disorder: a combined retrospective and prospective study.

Pardanani A, Baek JY, Li CY, Butterfield JH, Tefferi A. Pardanani A, et al. Mayo Clin Proc. 2002 Nov;77(11):1169-75. doi: 10.4065/77.11.1169. Mayo Clin Proc. 2002. PMID: 12440552

8

Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders.

Pardanani A, Reeder T, Porrata LF, Li CY, Tazelaar HD, Baxter EJ, Witzig TE, Cross NC, Tefferi A. Pardanani A, et al. Blood. 2003 May 1;101(9):3391-7. doi: 10.1182/blood-2002-10-3103. Epub 2002 Dec 27. Blood. 2003. PMID: 12506022 Free article.

9

Differential expression of CD2 on neoplastic mast cells in patients with systemic mast cell disease with and without an associated clonal haematological disorder.

Pardanani A, Kimlinger TK, Reeder TL, Li CY, Tefferi A. Pardanani A, et al. Br J Haematol. 2003 Feb;120(4):691-4. doi: 10.1046/j.1365-2141.2003.04125.x. Br J Haematol. 2003. PMID: 12588358

10

2-Chlorodeoxyadenosine therapy for disseminated Langerhans cell histiocytosis.

Pardanani A, Phyliky RL, Li CY, Tefferi A. Pardanani A, et al. Mayo Clin Proc. 2003 Mar;78(3):301-6. doi: 10.4065/78.3.301. Mayo Clin Proc. 2003. PMID: 12630583

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results